

Polsinelli Represents Alloy in ASO Platform Collaboration with Biogen

(April 14, 2026) Led by Shareholder Christopher P. Simpson, Polsinelli recently represented Alloy Therapeutics (Alloy), a biotechnology ecosystem company dedicated to democratizing access to cutting-edge drug discovery technologies, in a multi-target collaboration and license agreement with Biogen to advance the use of Alloy's AntiClastic™ ASO Platform, an antisense oligonucleotide technology used to support the design and development of therapeutics.

Under the agreement, Biogen will leverage Alloy's AntiClastic™ ASO platform to support the discovery and development of therapeutics across multiple targets.

This transaction highlights the growing importance of platform-driven partnerships in the life sciences sector and positions Alloy to continue pursuing innovative treatments with the potential to benefit patients.

More information about this collaboration can be found [here](#).

The Polsinelli team included Christopher P. Simpson and Izzy C. Drake.

About Polsinelli

Polsinelli is an Am Law 100 firm with more than 1,200 attorneys in over 25 offices nationwide. Recognized as one of the top firms for excellent client service and client relationships, Polsinelli is committed to meeting our clients' expectations of what a law firm should be. Our attorneys provide value through practical legal counsel infused with business insight, offering comprehensive corporate, transactional, litigation and regulatory services with a focus on health care, real estate, finance, technology, private equity and life sciences. Polsinelli PC, Polsinelli LLP in California, Polsinelli PC (Inc) in Florida.